Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
ACR Open Rheumatol ; 3(3): 173-184, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33570260

ABSTRACT

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. METHODS: IRs (number of first events/100 patient-years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow-up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable-adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long-term (malignancy and death) events. VTEs were assessed descriptively. RESULTS: For MACE, SIEs, and HZ, 1999 (3152.1 patient-years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient-years) and 6354 (16 670.8 patient-years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS-trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43-3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13-0.54) and 0.33 (0.24-0.45) for tofacitinib and bDMARDs, respectively. CONCLUSION: In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.

2.
J Rheumatol ; 47(7): 959-967, 2020 07 01.
Article in English | MEDLINE | ID: mdl-31371657

ABSTRACT

OBJECTIVE: To assess longterm safety in a US cohort of patients with rheumatoid arthritis (RA) treated with adalimumab (ADA) in real-world clinical care settings. METHODS: This observational study analyzed the longterm incidence of safety outcomes among patients with RA initiating ADA, using data from the Corrona RA registry. Patients were adults (≥ 18 yrs) who initiated ADA treatment between January 2008 and June 2017, and who had at least 1 followup visit. RESULTS: In total, 2798 ADA initiators were available for analysis, with a mean age of 54.5 years, 77% female, and mean disease duration of 8.3 years. Nearly half (48%) were biologic-naive, and 9% were using prednisone ≥ 10 mg at ADA initiation. The incidence rates per 100 person-years for serious infections, congestive heart failure requiring hospitalization, malignancy (excluding nonmelanoma skin cancer), and all-cause mortality were 1.86, 0.15, 0.64, and 0.33, respectively. The incidence of serious infections was higher in the first year of therapy (3.44, 95% CI 2.45-4.84) than in subsequent years, while other measured adverse effects did not vary substantially by duration of exposure. The median time to ADA discontinuation was 11 months, while the median time to first serious infection among those experiencing a serious infection event was 12 months. CONCLUSION: Analysis of longterm data from this prospective real-world registry demonstrated a safety profile consistent with previous studies in patients with RA. This analysis did not identify any new safety signals associated with ADA treatment and provides guidance for physicians prescribing ADA for extended periods.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Adalimumab/adverse effects , Adult , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Female , Humans , Male , Middle Aged , Prospective Studies , Registries , Treatment Outcome
3.
Arthritis Care Res (Hoboken) ; 70(3): 379-387, 2018 03.
Article in English | MEDLINE | ID: mdl-28544704

ABSTRACT

OBJECTIVE: To assess the feasibility and efficacy of implementing a treat-to-target approach versus usual care in a US-based cohort of rheumatoid arthritis patients. METHODS: In this behavioral intervention trial, rheumatology practices were cluster-randomized to provide treat-to-target care or usual care. Eligible patients with moderate/high disease activity (Clinical Disease Activity Index [CDAI] score >10) were followed for 12 months. Both treat-to-target and usual care patients were seen every 3 months. Treat-to-target providers were to have monthly visits with treatment acceleration at a minimum of every 3 months in patients with CDAI score >10; additional visits and treatment acceleration were at the discretion of usual care providers and patients. Coprimary end points were feasibility, assessed by rate of treatment acceleration conditional on CDAI score >10, and achievement of low disease activity (LDA; CDAI score ≤10) by an intent-to-treat analysis. RESULTS: A total of 14 practice sites per study arm were included (246 patients receiving treat-to-target and 286 receiving usual care). The groups had similar baseline demographic and clinical characteristics. Rates of treatment acceleration (treat-to-target 47% versus usual care 50%; odds ratio [OR] 0.92 [95% confidence interval (95% CI) 0.64, 1.34]) and achievement of LDA (treat-to-target 57% versus usual care 55%; OR 1.05 [95% CI 0.60, 1.84]) were similar between groups. Treat-to-target providers reported patient reluctance and medication lag time as common barriers to treatment acceleration. CONCLUSION: This study is the first to examine the feasibility and efficacy of a treat-to-target approach in typical US rheumatology practice. Treat-to-target care was not associated with increased likelihood of treatment acceleration or achievement of LDA, and barriers to treatment acceleration were identified.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Attitude of Health Personnel , Education, Medical, Continuing/methods , Health Knowledge, Attitudes, Practice , Inservice Training/methods , Rheumatologists/education , Rheumatologists/psychology , Aged , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/psychology , Clinical Decision-Making , Feasibility Studies , Female , Humans , Male , Medication Adherence , Middle Aged , Remission Induction , Time Factors , Treatment Outcome , United States
4.
J Vis Exp ; (98): e52553, 2015 Apr 01.
Article in English | MEDLINE | ID: mdl-25867947

ABSTRACT

Bone marrow transplantation (BMT) is often used to replace the bone marrow (BM) compartment of recipient mice with BM cells expressing a distinct biomarker isolated from donor mice. This technique allows for identification of donor-derived hematopoietic cells within the recipient mice, and can be used to isolate and characterize donor cells using various biochemical techniques. BMT typically relies on myeloablative conditioning with total body irradiation to generate niche space within the BM compartment of recipient mice for donor cell engraftment. The protocol we describe here uses myelosuppressive conditioning with the chemotherapeutic agent busulfan. Unlike irradiation, which requires the use of specialized facilities, busulfan conditioning is performed using intraperitoneal injections of 20 mg/kg busulfan until a total dose of 60-100 mg/kg has been administered. Moreover, myeloablative irradiation can have toxic side effects and requires successful engraftment of donor cells for survival of recipient mice. In contrast, busulfan conditioning using these doses is generally well tolerated and mice survive without donor cell support. Donor BM cells are isolated from the femurs and tibiae of mice ubiquitously expressing green fluorescent protein (GFP), and injected into the lateral tail vein of conditioned recipient mice. BM chimerism is estimated by quantifying the number of GFP+ cells within the peripheral blood following BMT. Levels of chimerism >80% are typically observed in the peripheral blood 3-4 weeks post-transplant and remain established for at least 1 year. As with irradiation, conditioning with busulfan and BMT allows for the accumulation of donor BM-derived cells within the central nervous system (CNS), particularly in mouse models of neurodegeneration. This busulfan-mediated CNS accumulation may be more physiological than total body irradiation, as the busulfan treatment is less toxic and CNS inflammation appears to be less extensive. We hypothesize that these cells can be genetically engineered to deliver therapeutics to the CNS.


Subject(s)
Bone Marrow Cells/drug effects , Bone Marrow Transplantation/methods , Busulfan/pharmacology , Myeloablative Agonists/pharmacology , Transplantation Chimera , Transplantation Conditioning/methods , Animals , Bone Marrow Cells/cytology , Central Nervous System/cytology , Mice , Mice, Inbred C57BL , Whole-Body Irradiation
5.
Neurosci Lett ; 588: 196-201, 2015 Feb 19.
Article in English | MEDLINE | ID: mdl-25582787

ABSTRACT

Previous work has suggested that bone marrow (BM)-derived cells (BMDCs) accumulate within the CNS and could potentially associate with ß-amyloid plaques in Alzheimer's disease (AD). To explore the accumulation of BMDCs in murine AD, we transplanted green fluorescent protein (GFP)-labeled BM cells into triple transgenic (3×Tg) and wild-type (wt) mice using non-irradiative myelosuppresive conditioning with busulfan (BU). We find that BU (80mg/kg) is sufficient to obtain adequate chimerism (>85%) in wt mice. In order to obtain appreciable non-irradiative chimerism in the 3×Tg mice (>80%), anti-asialo ganglio-N-tetraosylceramide (α-ASGM-1) antibody was also used to reduce natural killer cell function and thereby abrogate the hybrid resistance of the 3×Tg mouse strain. Using BU conditioning and α-ASGM-1 together, we observed sustained BM chimerism and BMDC accumulation within the CNS of the 3×Tg and wt mice. In cortex and hippocampus, BMDC accumulation was perivascular in distribution and similar between 3×Tg and wt mice, with no clear association between BMDCs and AD plaques. We conclude that non-irradiative BM chimerism can be achieved with BU in 3×Tg mice, but requires α-ASGM-1 (or similar appropriate NK-cell depletion). Use of this chimerism protocol permits BMDCs accumulation in the CNS of mixed strain recipient mice although BMDCs appear to be largely perivascular within cortex and hippocampus.


Subject(s)
Alzheimer Disease/pathology , Bone Marrow Cells/drug effects , Busulfan/pharmacology , Animals , Bone Marrow Cells/pathology , Bone Marrow Transplantation , Brain/pathology , Mice, Transgenic , Spinal Cord/pathology , Transplantation Chimera , Transplantation Conditioning
6.
BMC Musculoskelet Disord ; 15: 389, 2014 Nov 21.
Article in English | MEDLINE | ID: mdl-25416400

ABSTRACT

BACKGROUND: The treat-to-target (T2T) approach to the care of patients with rheumatoid arthritis involves using validated metrics to measure disease activity, frequent follow-up visits for patients with moderate to high disease activity, and escalation of therapy when patients have inadequate therapeutic response as assessed by standard disease activity scores. The study described is a newly launched cluster-randomized behavioral intervention to assess the feasibility and effectiveness of the T2T approach in US rheumatology practices. It is designed to identify patient and provider barriers to implementing T2T management. This initial paper focuses on the novel study design and methods created to provide these insights. METHODS/DESIGN: This trial cluster-randomizes rheumatology practices from the existing Corrona network of private and academic sites rather than patients within sites or individual investigators to provide either T2T or usual care (UC) for qualified patients who meet the 2010 revised American College of Rheumatology criteria for the diagnosis of rheumatoid arthritis and have moderate to high disease activity. Specific medication choices are left to the investigator and patient, rather than being specified in the protocol. Enrollment is expected to be completed by the end of 2013, with 30 practices randomized and enrolling a minimum of 530 patients. During the 12-month follow-up, visits are mandated as frequently as monthly in patients with active disease in the T2T group and every 3 months for the UC group. Safety data are collected at each visit. The coprimary endpoints include a comparison of the proportion of patients achieving low disease activity in the T2T and UC groups and assessment of the feasibility of implementing T2T in rheumatology practices, specifically assessment of the rates of treatment acceleration, frequency of visits, time to next visit conditional on disease activity, and probability of acceleration conditional on disease activity in the 2 groups. DISCUSSION: This cluster-randomized behavioral intervention study will provide valuable insights on the outcomes and feasibility of employing a T2T treatment approach in clinical practice in the United States. TRIAL REGISTRATION: NCT01407419.


Subject(s)
Arthritis, Rheumatoid/therapy , Drug Delivery Systems/methods , Rheumatology/methods , Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/epidemiology , Cluster Analysis , Drug Delivery Systems/trends , Feasibility Studies , Follow-Up Studies , Humans , Rheumatology/trends , Treatment Outcome
7.
PLoS One ; 8(4): e60661, 2013.
Article in English | MEDLINE | ID: mdl-23593276

ABSTRACT

Myeloablative preconditioning using irradiation is the most commonly used technique to generate rodents having chimeric bone marrow, employed for the study of bone marrow-derived cell accumulation in the healthy and diseased central nervous system. However, irradiation has been shown to alter the blood-brain barrier, potentially creating confounding artefacts. To better study the potential of bone marrow-derived cells to function as treatment vehicles for neurodegenerative diseases alternative preconditioning regimens must be developed. We treated transgenic mice that over-express human mutant superoxide dismutase 1, a model of amyotrophic lateral sclerosis, with busulfan to determine whether this commonly used chemotherapeutic leads to stable chimerism and promotes the entry of bone marrow-derived cells into spinal cord. Intraperitoneal treatment with busulfan at 60 mg/kg or 80 mg/kg followed by intravenous injection of green fluorescent protein-expressing bone marrow resulted in sustained levels of chimerism (~80%). Bone marrow-derived cells accumulated in the lumbar spinal cord of diseased mice at advanced stages of pathology at both doses, with limited numbers of bone marrow derived cells observed in the spinal cords of similarly treated, age-matched controls; the majority of bone marrow-derived cells in spinal cord immunolabelled for macrophage antigens. Comparatively, significantly greater numbers of bone marrow-derived cells were observed in lumbar spinal cord following irradiative myeloablation. These results demonstrate bone marrow-derived cell accumulation in diseased spinal cord is possible without irradiative preconditioning.


Subject(s)
Amyotrophic Lateral Sclerosis/immunology , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Bone Marrow Transplantation , Busulfan/pharmacology , Spinal Cord/immunology , Transplantation Conditioning/methods , Amyotrophic Lateral Sclerosis/enzymology , Amyotrophic Lateral Sclerosis/surgery , Animals , Bone Marrow Cells/immunology , Cell Count , Disease Models, Animal , Humans , Male , Mice , Mice, Inbred C57BL , Mutation , Phenotype , Superoxide Dismutase/genetics , Superoxide Dismutase-1
8.
Arch Public Health ; 70(1): 21, 2012 Aug 28.
Article in English | MEDLINE | ID: mdl-22958544

ABSTRACT

BACKGROUND: Alzheimer's disease and other related dementias are public health priorities in the European Union due to their prevalence, cost and profound impact on society. Because of these pressing implications, the European Union decided to create a Joint Action to share knowledge about dementia and health policy in order to preserve the health, quality of life, autonomy and dignity of people living with dementia and their carers in Europe. METHODS: ALCOVE is a European Community-funded Joint Action coordinated by the HAS (French National Authority for Health) with a 24-month duration. The project's life cycle has been divided into the following four steps: (1) collection of existing information, (2) analysis of existing information and making comparisons across Member States, (3) identifying Evidence, Needs, and Priorities, (4) drafting recommendations and disseminating them. RESULTS: 19 countries are participating in the ALCOVE initiative. The project will publish its final findings in 2013. The project's objectives, participants, method, on-going procedures and work plans are already available on the ALCOVE website: http://www.alcove-project.eu/. Preliminary results show that recommendations will need to focus on clinical and epidemiological data collection, diagnostic system assessment, outstanding approaches for treating behavioural disorders, limiting antipsychotic use, and competence assessment in this vulnerable population. CONCLUSIONS: The European Member States involved are mobilized to share best health policy practices in order to tackle the challenge of dementia's threat on European health and social systems and to improve the quality of life and care for individuals and their family carers.

9.
J Public Health Manag Pract ; 17(1): 4-11, 2011.
Article in English | MEDLINE | ID: mdl-21135655

ABSTRACT

OBJECTIVES: A process evaluation was conducted to evaluate a newly established active influenza surveillance program that utilized 6 sentinel hospitals to collect epidemiologic information for influenza-like illness admissions. Objectives were to determine whether the new system was implemented successfully and met surveillance objectives, including determination of the proportion of patients with 2009 H1N1 influenza, extent of disease severity, and identifying high-risk groups. METHODS: Timeliness and data quality were assessed through analysis of electronic case report form completion and timing of specimen collection and submission to public health laboratories for influenza testing. Simplicity and accessibility of the surveillance system were assessed through a survey of hospital-based surveillance staff. RESULTS: The median number of days from admission to initial reporting was 5 days. The completeness of core variables was more than 98%, 96.2% for complications, and 92.6% for underlying medical conditions. Among influenza-like illness admissions, 77.8% had a specimen submitted for confirmatory testing. Eighty-nine percent of survey respondents found guidance provided by New York State Department of Health to be helpful and case report forms easy to use. CONCLUSIONS: This project was implemented within a context of limited time and resources. Certain aspects of planning, such as securing necessary staffing at some hospitals, could not be carried out prior to implementation. Resource limitations necessitated controls on the numbers of specimens submitted each week. Some reporting lags were noted because of delays in data entry. Reporting timeframes allowed for timely data summarization for internal decision making. Maintaining frequent contact with sentinel sites promoted report completeness, timeliness, and consistency across sites. These results highlight the value of sentinel surveillance methodology and challenges of rapidly deploying a new active surveillance system for an emergent disease.


Subject(s)
Hospitalization/statistics & numerical data , Influenza A Virus, H1N1 Subtype , Influenza, Human/epidemiology , Process Assessment, Health Care/methods , Sentinel Surveillance , Data Collection/standards , Health Resources , Hospitalization/trends , Humans , Influenza, Human/complications , Influenza, Human/diagnosis , Influenza, Human/virology , Medical Staff, Hospital/education , Medical Staff, Hospital/standards , New York/epidemiology , Program Evaluation , Reverse Transcriptase Polymerase Chain Reaction/methods , Specimen Handling/methods , Specimen Handling/standards , Time Factors , Workflow
10.
J Public Health Manag Pract ; 17(1): 12-9, 2011.
Article in English | MEDLINE | ID: mdl-21135656

ABSTRACT

OBJECTIVE: To better understand the severity of 2009 H1N1 influenza disease, enhanced surveillance of patients hospitalized with influenza was conducted during the 2009-2010 influenza season in New York State through existing Emerging Infections Program surveillance and a newly established sentinel hospital surveillance program. The 2 surveillance systems were compared to determine consistency across surveillance modalities and reveal the strengths and weaknesses of each to accomplish comprehensive influenza surveillance. DESIGN: Similar variables from the aggregate data collected from each system were compared and differences were analyzed in detail. SETTING: New York State. PARTICIPANTS: Hospitalized adult and pediatric patients detected through 2 influenza surveillance programs. MAIN OUTCOME MEASURES: Significant differences in age distribution, timing of illness onset, illness complications, underlying medical conditions, critical care admissions, use of mechanical ventilation, and illness outcomes. RESULTS: Both surveillance systems saw the highest numbers of confirmed influenza infection among patients hospitalized in early fall 2009, with sharp declines thereafter. Sentinel hospital surveillance continued to detect hospitalizations for influenza-like illness that were not due to 2009 H1N1 influenza well into March 2010. Compared to influenza surveillance conducted through the Emerging Infections Program, the sentinel hospital influenza surveillance program tended to detect a sicker population of children and adults, including a higher rate of critical illness and mechanical ventilation, and among adults, higher rates of some underlying medical conditions. There were no differences in disease outcomes detected between the 2 systems. CONCLUSIONS: Although the 2 surveillance systems were complementary, inherent methodologic variations revealed important differences at season conclusion. The lessons learned should be used to determine the best way to allocate resources to meet the needs of future state and national influenza surveillance efforts.


Subject(s)
Communicable Diseases, Emerging/epidemiology , Hospitalization/statistics & numerical data , Influenza A Virus, H1N1 Subtype , Influenza, Human/epidemiology , Sentinel Surveillance , Adolescent , Adult , Age Distribution , Body Mass Index , Child , Child, Preschool , Communicable Diseases, Emerging/complications , Communicable Diseases, Emerging/diagnosis , Communicable Diseases, Emerging/virology , Data Collection , Female , Hospitalization/trends , Humans , Infant , Influenza, Human/complications , Influenza, Human/diagnosis , Influenza, Human/virology , Intensive Care Units/statistics & numerical data , Male , New York/epidemiology , Program Evaluation , Severity of Illness Index
11.
J Infus Nurs ; 30(2): 96-104; quiz 120, 2007.
Article in English | MEDLINE | ID: mdl-17413494

ABSTRACT

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovial membranes and progressive joint destruction. Increased understanding of the immunopathology of RA has resulted in the development of new therapies to manage the disease, including several infusion-based therapies. Abatacept, a selective costimulation modulator, has been shown to be effective in clinical trials. Abatacept has a mechanism of action that is different from any other biologic RA therapy, and it provides a valuable alternative for RA patients. This article provides practical guidance for nurses to ensure safe administration and to maximize patient outcomes with abatacept.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Immunoconjugates/therapeutic use , Abatacept , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/nursing , Education, Continuing , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/adverse effects , Infusions, Intravenous
SELECTION OF CITATIONS
SEARCH DETAIL
...